Your browser doesn't support javascript.
loading
CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits.
Koornneef, Annemart; Vanshylla, Kanika; Hardenberg, Gijs; Rutten, Lucy; Strokappe, Nika M; Tolboom, Jeroen; Vreugdenhil, Jessica; Boer, Karin Feddes-de; Perkasa, Aditya; Blokland, Sven; Burger, Judith A; Huang, Wei-Chiao; Lovell, Jonathan F; van Manen, Danielle; Sanders, Rogier W; Zahn, Roland C; Schuitemaker, Hanneke; Langedijk, Johannes P M; Wegmann, Frank.
Affiliation
  • Koornneef A; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Vanshylla K; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Hardenberg G; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Rutten L; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Strokappe NM; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Tolboom J; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Vreugdenhil J; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Boer KF; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Perkasa A; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Blokland S; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Burger JA; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Huang WC; Department of Biomedical Engineering, University at Buffalo, Buffalo, NY, USA.
  • Lovell JF; Department of Biomedical Engineering, University at Buffalo, Buffalo, NY, USA.
  • van Manen D; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Sanders RW; Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Zahn RC; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Schuitemaker H; Janssen Vaccines & Prevention, Leiden, The Netherlands.
  • Langedijk JPM; Janssen Vaccines & Prevention, Leiden, The Netherlands. hlangedijk@forge-bio.com.
  • Wegmann F; ForgeBio, Amsterdam, The Netherlands. hlangedijk@forge-bio.com.
Nat Commun ; 15(1): 3128, 2024 Apr 11.
Article in En | MEDLINE | ID: mdl-38605096
ABSTRACT
One of the strategies towards an effective HIV-1 vaccine is to elicit broadly neutralizing antibody responses that target the high HIV-1 Env diversity. Here, we present an HIV-1 vaccine candidate that consists of cobalt porphyrin-phospholipid (CoPoP) liposomes decorated with repaired and stabilized clade C HIV-1 Env trimers in a prefusion conformation. These particles exhibit high HIV-1 Env trimer decoration, serum stability and bind broadly neutralizing antibodies. Three sequential immunizations of female rabbits with CoPoP liposomes displaying a different clade C HIV-1 gp140 trimer at each dosing generate high HIV-1 Env-specific antibody responses. Additionally, serum neutralization is detectable against 18 of 20 multiclade tier 2 HIV-1 strains. Furthermore, the peak antibody titers induced by CoPoP liposomes can be recalled by subsequent heterologous immunization with Ad26-encoded membrane-bound stabilized Env antigens. Hence, a CoPoP liposome-based HIV-1 vaccine that can generate cross-clade neutralizing antibody immunity could potentially be a component of an efficacious HIV-1 vaccine.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV-1 / AIDS Vaccines / Env Gene Products, Human Immunodeficiency Virus Limits: Animals Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2024 Document type: Article Affiliation country: Países Bajos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV-1 / AIDS Vaccines / Env Gene Products, Human Immunodeficiency Virus Limits: Animals Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2024 Document type: Article Affiliation country: Países Bajos